posted in Spine Surgery
« Stem Cells May Provide Non Surgical Treatment for Spinal Cord Injuries | Implants for Patient with Lupus and Treated with Steriods? »
Print This PostOsteotech, Inc. (Nasdaq: OSTE - News), a leader in the emerging field of biologic solutions for regenerative healing, announced that the United States Food and Drug Administration (”FDA”) has cleared its 510(k) submission for Plexur M(TM) Biocomposite for use in spinal applications. In spinal applications, Plexur M(TM) may be used in conjunction with autograft as a bone void filler.
Sam Owusu-Akyaw, Osteotech’s President and Chief Executive Officer, stated, “We are very pleased to receive FDA clearance for use of Plexur M(TM) in the spine. Plexur M(TM) is the second, of what we hope to be many more, bone-polymer biocomposites developed under our proprietary Plexur Technology.”
The Plexur Technology is designed to utilize bone tissue for procedure-specific surgical applications in combination with a wide variety of polymers. On a worldwide basis, Osteotech currently controls 33 patents and over 65 pending patent applications covering the Plexur Technology for human and xenograft bone tissue
Leave a Comment
Comment Guidelines: This is a forum for dentists for intelligent discussion. No insults. No outside links. No promotional comments. Though we require an email to route questionable comments to our editors, we will NEVER publish your email. Consumers & Patients: Please do NOT post dental questions here. Instead Visit ChooseDentalImplants.com to get Expert Advice for Implants.
Note: At times your comment may not appear on the website immediately, because it has been sent to our editors for approval. Once approved, we will publish the comment. There is NO need to resubmit your comment, if it does not appear on the website immediately.